Biocept, Inc. (BIOC) Receives Consensus Rating of “Hold” from Brokerages
Shares of Biocept, Inc. (NASDAQ:BIOC) have received a consensus rating of “Hold” from the five brokerages that are covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating and three have assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $2.50.
Several analysts have issued reports on BIOC shares. ValuEngine raised Biocept from a “strong sell” rating to a “sell” rating in a research report on Thursday, July 6th. Zacks Investment Research cut Biocept from a “buy” rating to a “hold” rating in a research report on Wednesday, July 12th. Finally, Westpark Capital reaffirmed an “outperform” rating on shares of Biocept in a research report on Thursday, August 3rd.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/12/biocept-inc-bioc-receives-consensus-rating-of-hold-from-brokerages.html.
A hedge fund recently raised its stake in Biocept stock. Vanguard Group Inc. increased its position in Biocept, Inc. (NASDAQ:BIOC) by 9.6% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 764,351 shares of the medical research company’s stock after acquiring an additional 66,746 shares during the period. Vanguard Group Inc. owned approximately 2.87% of Biocept worth $1,048,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 6.92% of the stock is currently owned by institutional investors.
Biocept (NASDAQ:BIOC) last announced its earnings results on Thursday, August 10th. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.01). The company had revenue of $1.28 million for the quarter, compared to the consensus estimate of $1.23 million. Biocept had a negative net margin of 359.48% and a negative return on equity of 550.35%. On average, equities analysts expect that Biocept will post ($0.79) EPS for the current year.
Biocept Company Profile
Biocept, Inc is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company’s Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample.
Receive News & Ratings for Biocept Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept Inc. and related companies with MarketBeat.com's FREE daily email newsletter.